Replies to post #49474 on Biotech Values

[masterlongevity]

anything about this on the call? i ahven't had time to listen yet

[EyeGuy]

Another exception: therapies for use in combo with Avasting/Luc with a different MOA (provided they are cost-effective). Assume here you are also talking only about wet AMD and not broader indication (i.e., dry AMD) which is still an unmet need.